Harmony Biosciences Holdings, Inc. HRMY 深 滬
等待開盤 05-27 09:30:00 美东时间
30.09
-0.060
-0.20%
華盛通- 最 高30.63
- 今 開30.15
- 成交量 69.19万股
- 最 低 30.08
- 昨 收 30.15
- 總市值 17.42亿
- 52周最高 40.87
- 市盈率 靜 11.10
- 換手率 1.20%
- 52周最低 25.52
- 委 比 96.44%
- 總股本 5789.27万
- 歷史最高 62.085
- 量 比 1.12
- 振 幅 1.82%
- 歷史最低 18.6112
- 每 手 1
- 風險率 3.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harmony Biosciences director Geno J. Germano files initial beneficial ownership statement
Harmony Biosciences director Geno J. Germano files initial beneficial ownership statement Harmony Biosciences director Geno J. Germano filed an initial Form 3 beneficial ownership statement dated May 14, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative art
05-19 09:51
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $29
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $25 to $29.
05-09 01:07
财报速睇 | Harmony Biosciences Holdings, Inc. 2026财年Q1营收2.15亿美元，同比增长16.6%；归母净利润0.32亿美元，同比下滑28.7%
华盛资讯5月7日讯，Harmony Biosciences Holdings, Inc.公布2026财年Q1业绩，公司Q1营收2.15亿美元，同比增长16.6%，归母净利润0.32亿美元，同比下滑28.7%。
05-07 21:47
财报速睇 | Harmony Biosciences Holdings, Inc. 2026财年Q1营收2.15亿美元，同比增长16.6%；归母净利润0.32亿美元，同比下滑28.7%
华盛资讯5月7日讯，Harmony Biosciences Holdings, Inc.公布2026财年Q1业绩，公司Q1营收2.15亿美元，同比增长16.6%，归母净利润0.32亿美元，同比下滑28.7%。
05-07 20:31
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
05-07 19:43
Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.69 by 20.29 percent. This is a 46.6 percent decrease over earnings of $1.03 per share
05-07 19:38
Harmony Bio spikes after new Wakix patent litigation
Shares of Harmony Biosciences (HRMY) climbed on Tuesday after Mizuho issued bullish remarks on the stock, citing a new patent litigation filed by the company to fight generics targeting its sleep diso...
04-22 01:23
Harmony Biosciences Appoints Glenn Reicin CFO, Effective Immediately; Co. Reiterates 2026 Net Product Revenue Outlook Range $1B - $1.04B
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial
04-14 20:13
Harmony Biosciences announces annual shareholder meeting via webcast
Harmony Biosciences announces annual shareholder meeting via webcast Harmony Biosciences set annual stockholder meeting for May 14, 2026, to be held virtually. Ballot includes election of four Class III directors to serve through 2029, including nominees Geno Germano, Troy Ignelzi, Ron Philip, Andre
04-03 20:02
